The future trajectory of adverse outcome pathways: a commentary

被引:0
|
作者
Fiona Sewell
Nichola Gellatly
Maria Beaumont
Natalie Burden
Richard Currie
Lolke de Haan
Thomas H. Hutchinson
Miriam Jacobs
Catherine Mahony
Ian Malcomber
Jyotigna Mehta
Graham Whale
Ian Kimber
机构
[1] National Centre for the Replacement,School of Geography, Earth and Environmental Sciences
[2] Refinement and Reduction of Animals in Research (NC3Rs),Faculty of Biology, Medicine and Health
[3] GlaxoSmithKline,undefined
[4] Syngenta Ltd.,undefined
[5] Jealott’s Hill International Research Centre,undefined
[6] MedImmune,undefined
[7] University of Plymouth,undefined
[8] Public Health England,undefined
[9] Procter and Gamble Company,undefined
[10] Unilever,undefined
[11] Safety and Environmental Assurance Centre,undefined
[12] Dow AgroSciences,undefined
[13] European Development Centre,undefined
[14] Shell,undefined
[15] Health,undefined
[16] Shell Centre,undefined
[17] University of Manchester,undefined
来源
Archives of Toxicology | 2018年 / 92卷
关键词
Adverse outcome pathways (AOPs); Hazard identification; Safety assessment; Risk assessment;
D O I
暂无
中图分类号
学科分类号
摘要
The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis for addressing some of those challenges and opportunities.
引用
收藏
页码:1657 / 1661
页数:4
相关论文
共 50 条
  • [31] Liver Adverse Outcome Pathways: What's in for the Hepatologist?
    Vinken, Mathieu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2020, 29 (04) : 659 - 664
  • [32] A Modular Approach for Assembly of Quantitative Adverse Outcome Pathways
    Foran, Christy M.
    Rycroft, Taylor
    Keisler, Jeffrey
    Perkins, Edward J.
    Linkov, Igor
    Garcia-Reyero, Natalia
    ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2019, 36 (03) : 353 - 362
  • [33] A weight of evidence assessment approach for adverse outcome pathways
    Collier, Zachary A.
    Gust, Kurt A.
    Gonzalez-Morales, Benette
    Gong, Ping
    Wilbanks, Mitchell S.
    Linkov, Igor
    Perkins, Edward J.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2016, 75 : 46 - 57
  • [34] Adverse outcome pathways: opportunities, limitations and open questions
    Marcel Leist
    Ahmed Ghallab
    Rabea Graepel
    Rosemarie Marchan
    Reham Hassan
    Susanne Hougaard Bennekou
    Alice Limonciel
    Mathieu Vinken
    Stefan Schildknecht
    Tanja Waldmann
    Erik Danen
    Ben van Ravenzwaay
    Hennicke Kamp
    Iain Gardner
    Patricio Godoy
    Frederic Y. Bois
    Albert Braeuning
    Raymond Reif
    Franz Oesch
    Dirk Drasdo
    Stefan Höhme
    Michael Schwarz
    Thomas Hartung
    Thomas Braunbeck
    Joost Beltman
    Harry Vrieling
    Ferran Sanz
    Anna Forsby
    Domenico Gadaleta
    Ciarán Fisher
    Jens Kelm
    David Fluri
    Gerhard Ecker
    Barbara Zdrazil
    Andrea Terron
    Paul Jennings
    Bart van der Burg
    Steven Dooley
    Annemarie H. Meijer
    Egon Willighagen
    Marvin Martens
    Chris Evelo
    Enrico Mombelli
    Olivier Taboureau
    Alberto Mantovani
    Barry Hardy
    Bjorn Koch
    Sylvia Escher
    Christoph van Thriel
    Cristina Cadenas
    Archives of Toxicology, 2017, 91 : 3477 - 3505
  • [35] Adverse outcome pathways: opportunities, limitations and open questions
    Leist, Marcel
    Ghallab, Ahmed
    Graepel, Rabea
    Marchan, Rosemarie
    Hassan, Reham
    Bennekou, Susanne Hougaard
    Limonciel, Alice
    Vinken, Mathieu
    Schildknecht, Stefan
    Waldmann, Tanja
    Danen, Erik
    van Ravenzwaay, Ben
    Kamp, Hennicke
    Gardner, Iain
    Godoy, Patricio
    Bois, Frederic Y.
    Braeuning, Albert
    Reif, Raymond
    Oesch, Franz
    Drasdo, Dirk
    Hoehme, Stefan
    Schwarz, Michael
    Hartung, Thomas
    Braunbeck, Thomas
    Beltman, Joost
    Vrieling, Harry
    Sanz, Ferran
    Forsby, Anna
    Gadaleta, Domenico
    Fisher, Ciaran
    Kelm, Jens
    Fluri, David
    Ecker, Gerhard
    Zdrazil, Barbara
    Terron, Andrea
    Jennings, Paul
    van der Burg, Bart
    Dooley, Steven
    Meijer, Annemarie H.
    Willighagen, Egon
    Martens, Marvin
    Evelo, Chris
    Mombelli, Enrico
    Taboureau, Olivier
    Mantovani, Alberto
    Hardy, Barry
    Koch, Bjorn
    Escher, Sylvia
    van Thriel, Christoph
    Cadenas, Cristina
    ARCHIVES OF TOXICOLOGY, 2017, 91 (11) : 3477 - 3505
  • [36] Impact and implication of causal terminology in adverse outcome pathways
    Zhou, Z.
    Pennings, J.
    Sahlin, U.
    TOXICOLOGY LETTERS, 2024, 399 : S258 - S258
  • [37] In response: Adverse outcome pathways-An industry perspective
    Wheeler, James R.
    Weltje, Lennart
    ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2015, 34 (09) : 1937 - 1938
  • [38] Systems toxicology to support development of adverse outcome pathways
    Grafstrom, R. C.
    Hongisto, V.
    Kohonen, P. J.
    Nymark, P.
    TOXICOLOGY LETTERS, 2019, 314 : S25 - S25
  • [39] Adverse outcome pathways - development and potential regulatory application
    Rossi Lima, Thania Rios
    de Souza, Nathalia Pereira
    Pereira, Lilian Cristina
    Viana de Camargo, Joao Lauro
    VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA, 2021, 9 (03): : 2 - 13
  • [40] Outcome-based education: the future is today - Commentary
    Harden, Ronald M.
    MEDICAL TEACHER, 2007, 29 (07) : 625 - 629